Financial PositionThe company has $73 million in cash, which provides runway for all ongoing operations into 2027.
Preclinical DataThe positive preclinical data from the GLP toxicology study of SL-325 presented at ECCO builds an encouraging profile for further development.
Product DevelopmentShattuck's pivot into the inflammatory bowel disease market is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.